HC Wainwright set a $48.00 target price on Uniqure (NASDAQ:QURE) in a research note released on Wednesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other research analysts have also recently weighed in on QURE. Cantor Fitzgerald set a $58.00 price target on shares of Uniqure and gave the stock a buy rating in a report on Saturday, August 11th. BidaskClub raised shares of Uniqure from a sell rating to a hold rating in a report on Friday, October 19th. Chardan Capital reaffirmed a buy rating and issued a $50.00 price target on shares of Uniqure in a report on Thursday, October 18th. Zacks Investment Research cut shares of Uniqure from a buy rating to a hold rating in a report on Wednesday, October 17th. Finally, Cowen reaffirmed a buy rating on shares of Uniqure in a report on Monday, August 13th. Three research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Uniqure currently has a consensus rating of Buy and a consensus price target of $49.67.

Shares of Uniqure stock traded down $0.67 during trading on Wednesday, hitting $27.23. The stock had a trading volume of 246,155 shares, compared to its average volume of 293,037. The stock has a market cap of $954.79 million, a P/E ratio of -9.26 and a beta of 0.78. Uniqure has a 12 month low of $13.71 and a 12 month high of $43.23. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.36 and a current ratio of 8.36.

Uniqure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.03. The firm had revenue of $3.15 million for the quarter, compared to analysts’ expectations of $3.37 million. Uniqure had a negative net margin of 725.04% and a negative return on equity of 65.36%. Sell-side analysts predict that Uniqure will post -2.44 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Gagnon Securities LLC bought a new position in Uniqure in the second quarter valued at $209,000. Ladenburg Thalmann Financial Services Inc. increased its stake in Uniqure by 276.5% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,400 shares of the biotechnology company’s stock valued at $150,000 after acquiring an additional 4,700 shares during the last quarter. Atria Investments LLC bought a new position in Uniqure in the second quarter valued at $247,000. Trexquant Investment LP bought a new position in Uniqure in the second quarter valued at $272,000. Finally, Oppenheimer & Co. Inc. bought a new position in Uniqure in the third quarter valued at $279,000. 59.10% of the stock is currently owned by institutional investors and hedge funds.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

See Also: Is the Dow Jones Industrial Average (DJIA) still relevant?

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.